Lyell Immunopharma (LYEL)
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
📈 **POSITIVE** • High confidence analysis (81%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (86%) **Content type:** Clinical